Ex Vivo-Generated Tolerogenic Dendritic Cells: Hope for a Definitive Therapy of Autoimmune Diseases

• Published in: Current Issues in Molecular Biology Vol. 46; no. 5; pp. 4035 - 4048
• Main Authors: Jonny, Sitepu, Enda Cindylosa, Nidom, Chairul A., Wirjopranoto, Soetojo, Sudiana, I. Ketut, Ansori, Arif N. M., Putranto, Terawan Agus
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.05.2024
• Subjects: Antigens; autoimmune disease; Autoimmune diseases; B cells; cellular immunotherapy; Dendritic cells; Health aspects; immune tolerance; Immunosuppressive agents; Immunotherapy; Medical research; Medicine, Experimental; systemic lupus erythematosus; Indonesia; immune tolerance; systemic lupus erythematosus; cellular immunotherapy; dendritic cells; autoimmune disease
• ISSN: 1467-3045; 1467-3037; 1467-3045
• DOI: 10.3390/cimb46050249

Current therapies for autoimmune diseases are immunosuppressant agents, which have many debilitating side effects. However, dendritic cells (DCs) can induce antigen-specific tolerance. Tolerance restoration mediated by ex vivo-generated DCs can be a therapeutic approach. Therefore, in this review, we summarize the conceptual framework for developing ex vivo-generated DC strategies for autoimmune diseases. First, we will discuss the role of DCs in developing immune tolerance as a foundation for developing dendritic cell-based immunotherapy for autoimmune diseases. Then, we also discuss relevant findings from pre-clinical and clinical studies of ex vivo-generated DCs for therapy of autoimmune diseases. Finally, we discuss problems and challenges in dendritic cell therapy in autoimmune diseases. Throughout the article, we discuss autoimmune diseases, emphasizing SLE.